Wednesday, June 10, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands clinical programs — 84 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
84
Drugs
37
Patents
379
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Alnylam Netherlands projects

84 ClinicalTrials.gov programs sponsored by Alnylam Netherlands.

Alnylam Netherlands has 84 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

84 programs

Clinical programs

Page 1 of 2

  1. ALN-AGT01-008

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  2. ALN-TTR02-011

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  3. ALN-TTRSC02-002

    Alnylam Netherlands B.V.

    Hereditary Transthyretin Amyloidosis

    phase 3 small molecule active

    1 trial

  4. ALN-TTRSC02-003

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  5. ALN-TTRSC04-004

    Alnylam Netherlands B.V.

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy

    phase 3 small molecule active

    1 trial

  6. Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  7. Givosiran

    Alnylam Netherlands B.V.

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

  8. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  9. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  10. Nucresiran

    Alnylam Netherlands B.V.

    Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

    phase 3 small molecule active

    1 trial

  11. Nucresiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis With Cardiomyopathy

    phase 3 small molecule active

    1 trial

  12. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Familial

    phase 3 small molecule completed

    1 trial

  13. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis

    phase 3 small molecule completed

    1 trial

  14. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Hereditary

    phase 3 small molecule completed

    1 trial

  15. Placebo

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  16. Placebo

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 3 small molecule completed

    1 trial

  17. Placebo for Nucresiran, ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  18. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    phase 3 small molecule completed

    1 trial

  19. Vutrisiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule active

    2 trials

  20. Zilebesiran

    Alnylam Netherlands B.V.

    High Risk Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  21. patisiran (ALN-TTR02)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 3 small molecule completed

    1 trial

  22. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  23. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

  24. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  25. ALN-6400

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia

    phase 2 small molecule active

    1 trial

  26. ALN-6400

    Alnylam Netherlands B.V.

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  27. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

  28. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  29. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  30. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  31. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  32. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  33. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  34. ALN-XDH

    Alnylam Netherlands B.V.

    Gout

    phase 2 small molecule terminated

    1 trial

  35. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 2 small molecule completed

    1 trial

  36. Indapamide

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  37. Lumasiran

    Alnylam Netherlands B.V.

    Haemodialysis

    phase 2 small molecule active

    1 trial

  38. Lumasiran

    Alnylam Netherlands B.V.

    PH1

    phase 2 small molecule completed

    1 trial

  39. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 2 small molecule completed

    1 trial

  40. Lumasiran

    Alnylam Netherlands B.V.

    Recurrent Calcium Oxalate Kidney Stone Disease

    phase 2 small molecule terminated

    1 trial

  41. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  42. Patisiran

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  43. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  44. Placebo

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  45. Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy

    phase 2 small molecule active

    1 trial

  46. Placebo

    Alnylam Netherlands B.V.

    IgA Nephropathy (IgAN)

    phase 2 small molecule terminated

    1 trial

  47. Revusiran

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  48. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Alnylam Netherlands have?

84 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.